Antibodies blocking the interaction of PD-L1 on tumor cells and PD-1 on TILs may further enhance this response, as TILs already residing in the tumor remained functional, despite PD-L1 expression on tumor cells, likely resulting in a better and long-lasting tumor control. The gene discussed is CD274; the disease is neoplasm.